HEALTH OPTIMIZING BY SALVAGENE - WITH ARTIFICIAL BASED MEDICINE

Continually validating the latest scientific findings, we are developing them for the benefit of your personal health. Keep yourself informed about important changes and product related topics with the following PODCASTS and KEYNOTES: Health optimizing by Salvagene – with artificial based medicine.

Play the latest episode Subscribe to the podcast
HEALTH OPTIMIZING BY SALVAGENE - WITH ARTIFICIAL BASED MEDICINE

Latest episodes

Dr Robert Hess: New relief for Migraine sufferers as FDA approves AbbVie’s QULIPTA (Atogepant)

Dr Robert Hess: New relief for Migraine sufferers as FDA approves AbbVie’s QULIPTA (Atogepant)

‧ 4m 10s

Towards the end of September, Chicago-based biotechnology pharmaceutical giant AbbVie announced that the FDA had approved its QULIPTA (Atogepant) medication for the preventive treatment of episodic migraine in adults. The FDA has thus given the green light to the first and so far only oral CGRP (calcitonin gene-related peptide) receptor antagonist specifically formulated for the preventive treatment of migraine.

Peter J. Goadsby, professor at the University of California, Los Angeles, and at King’s College London, described the FDA approval of QULIPTA as a milestone in the treatment of migraine. Goadsby, who was awarded the prestigious Brain Prize in 2021 for...